Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients

INTRODUCTION: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have represented the prototype of targeted therapy in NSCLC. Patients with EGFR-mutant lung adenocarcinoma extract an extraordinary clinical benefit from EGFR-TKIs. However, the extent and duration of these respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Ji Eun, Hong, Mi Jeong, Lee, Shin Yup, Lee, Jang Hyuck, Choi, Jin Eun, Kang, Hyo-Gyoung, Do, Sook Kyung, Jeong, Ji Yun, Shin, Kyung Min, Lee, Won Kee, Choi, Sun Ha, Lee, Yong Hoon, Seo, Hye won, Yoo, Seung Soo, Lee, Jaehee, Cha, Seung Ick, Kim, Chang Ho, Park, Jae Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493114/
https://www.ncbi.nlm.nih.gov/pubmed/34629889
http://dx.doi.org/10.2147/PGPM.S329055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493114/
https://www.ncbi.nlm.nih.gov/pubmed/34629889
http://dx.doi.org/10.2147/PGPM.S329055

Ejemplares similares